IP Library › Granted Patent US 12,331,094
Granted Patent B2
US 12,331,094 · App. 17/046,509 · Granted Jun 17, 2025

Atrial natriuretic peptide engrafted antibodies

Inventors: Anke Mayer-Bartschmid (Wülfrath, DE); Damian Brockschnieder (Haan, DE); Marcel Geertz (Remscheid, DE); Simone Greven (Dormagen, DE); Lucas Hudson Hofmeister (Wuppertal, DE); Hannah Jörissen (Heiligenhaus, DE); Christoph Mahlert (Wuppertal, DE); Tobias Marquardt (Wuppertal, DE); Ilka Mathar (Düsseldorf, DE); Thomas Mondritzki (Essen, DE); Claudia Noack (Berlin, DE); Jan Tebbe (Cologne, DE); Stuart Walsh (Hamburg, DE); Ernst Weber (Langenfeld, DE); Andreas Wilmen (Cologne, DE); Frank Wunder (Wuppertal, DE)
Assignee: Bayer Aktiengesellschaft
C07K14/58A61K38/00C07K16/00A61K38/2242C07K2317/10C07K2317/565C07K2318/00C07K2318/10C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,094
App. No.
17/046,509
Granted
Jun 17, 2025
Kind
B2
Abstract

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Claims (204)

1. An antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, and wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls), and wherein:

the Ntls comprises at least 12 and up to 30 amino acid residues and the Ctls comprises at least 9 and up to 30 amino acid residues, and wherein:

i) in case of an incorporation of said heterologous amino acid sequence within CDRH1, the Ntls is present between amino acid residue HC res25 according to Kabat and the first amino acid residue of said ANP, and the Ctls is present between the last amino acid residue of said ANP and amino acid residue HC res35a according to Kabat; and/or

ii) in case of an incorporation of said heterologous amino acid sequence within CDRH2, the Ntls is present between amino acid residue HC res51 according to Kabat and the first amino acid residue of said ANP, and the Ctls is present between the last amino acid residue of said ANP and amino acid residue HC res57 according to Kabat; and/or

iii) in case of an incorporation of said heterologous amino acid sequence within CDRH3, the Ntls is present between amino acid residue HC res92 according to Kabat and the first amino acid residue of said ANP, and the Ctls is present between the last amino acid residue of said ANP and amino acid residue HC res106 according to Kabat; and/or

iv) in case of an incorporation of said heterologous amino acid sequence within CDRL1, the Ntls is present between amino acid residue LC res26 according to Kabat and the first amino acid residue of said ANP, and the Ctls is present between the last amino acid residue of said ANP and amino acid residue LC res 32 according to Kabat; and/or

v) in case of an incorporation of said heterologous amino acid sequence within CDRL2, the Ntls is present between amino acid residue LC res49 according to Kabat and the first amino acid residue of said ANP, and the Ctls is present between the last amino acid residue of said ANP and amino acid residue LC res57 according to Kabat; and/or

vi) in case of an incorporation of said heterologous amino acid sequence within CDRL3, the Ntls is present between amino acid residue LC res88 according to Kabat and the first amino acid residue of said ANP, and the Ctls is present between the last amino acid residue of said ANP and amino acid residue LC res98 according to Kabat; and

wherein:

i) said Ntls and said Ctls each comprise a GS linker sequence; or

ii) said Ntls and said Ctls each comprise a PN linker sequence; or

iii) said Ntls comprises the sequence of any one of SEQ ID NOs 1, 2 or 4 and said Ctls comprises the sequence of any one of SEQ ID NOs 1, 3 or 5; or

iv) said Ntls and said Ctls each comprise the sequence of SEQ ID NO 6; or

v) said Ntls comprises the sequence of SEQ ID NO 7 and said Ctls comprises the sequence of SEQ ID NO 8; or

vi) said Ntls comprises the sequence of SEQ ID NO 9 and said Ctls comprises the sequence of SEQ ID NO 10; or

vii) said Ntls comprises the sequence of SEQ ID NO 11 and said Ctls comprises the sequence of SEQ ID NO 12; or

viii) said Ntls comprises the sequence of SEQ ID NO 13 and said Ctls comprises the sequence of SEQ ID NO 14; or

ix) said Ntls and said Ctls each comprise the sequence of SEQ ID NO 15; or

x) said Ntls comprises the sequence of SEQ ID NO 9 and said Ctls comprises the sequence of SEQ ID NO 20; or

xi) said Ntls comprises the sequence of SEQ ID NO 21 and said Ctls comprises the sequence of SEQ ID NO 22, and

wherein said antibody or a fragment thereof is a human or humanized antibody or fragment thereof; and

wherein said antibody or fragment thereof is of the class IgG.

2. The antibody or fragment thereof according to claim 1 , wherein said ANP is selected from the group consisting of human ANP having the sequence of SEQ ID NO: 23 and a peptide having at least 95% sequence identity therewith.

3. The antibody or fragment thereof according to claim 1 , wherein said Ntls further comprises an anchoring element A1 at its C terminal end and/or said Ctls further comprises an anchoring element A2 at its N terminal end, and

wherein, when A1 and/or A2 are present, at least 60% of the amino acid residues of A1 and/or A2 are selected from glycine and serine residues.

4. The antibody or fragment thereof according to claim 1 , wherein;

i) the Ntls comprises the amino acid sequence of SEQ ID NO: 95 and the Ctls comprises the amino acid sequence of SEQ ID NO: 96; or

ii) the Ntls comprises the amino acid sequence of SEQ ID NO: 97 and the Ctls comprises the amino acid sequence of SEQ ID NO: 98; or

iii) the Ntls comprises the amino acid sequence of SEQ ID NO: 99 and the Ctls comprises the amino acid sequence of SEQ ID NO: 100; or

iv) the Ntls comprises the amino acid sequence of SEQ ID NO: 101 and the Ctls comprises the amino acid sequence of SEQ ID NO: 102; or

v) the Ntls comprises the amino acid sequence of SEQ ID NO: 103 and the Ctls comprises the amino acid sequence of SEQ ID NO: 102; or

vi) the Ntls comprises the amino acid sequence of SEQ ID NO: 105 and the Ctls comprises the amino acid sequence of SEQ ID NO: 106; or

vii) the Ntls comprises the amino acid sequence of SEQ ID NO: 119 and the Ctls comprises the amino acid sequence of SEQ ID NO: 120; or

viii) the Ntls comprises the amino acid sequence of SEQ ID NO: 121 and the Ctls comprises the amino acid sequence of SEQ ID NO: 122; or

ix) the Ntls comprises the amino acid sequence of SEQ ID NO: 123 and the Ctls comprises the amino acid sequence of SEQ ID NO: 124; or

x) the Ntls comprises the amino acid sequence of SEQ ID NO: 125 and the Ctls comprises the amino acid sequence of SEQ ID NO: 126; or

xi) the Ntls comprises the amino acid sequence of SEQ ID NO: 127 and the Ctls comprises the amino acid sequence of SEQ ID NO: 116; or

xii) the Ntls comprises the amino acid sequence of SEQ ID NO: 128 and the Ctls comprises the amino acid sequence of SEQ ID NO: 129; or

xiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 130 and the Ctls comprises the amino acid sequence of SEQ ID NO: 126; or

xiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 131 and the Ctls comprises the amino acid sequence of SEQ ID NO: 132; or

xv) the Ntls comprises the amino acid sequence of SEQ ID NO: 133 and the Ctls comprises the amino acid sequence of SEQ ID NO: 134; or

xvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 137 and the Ctls comprises the amino acid sequence of SEQ ID NO: 116; or

xvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 138 and the Ctls comprises the amino acid sequence of SEQ ID NO: 116; or

xviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 139 and the Ctls comprises the amino acid sequence of SEQ ID NO: 140; or

xix) the Ntls comprises the amino acid sequence of SEQ ID NO: 145 and the Ctls comprises the amino acid sequence of SEQ ID NO: 146; or

xx) the Ntls comprises the amino acid sequence of SEQ ID NO: 147 and the Ctls comprises the amino acid sequence of SEQ ID NO: 146; or

xxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 145 and the Ctls comprises the amino acid sequence of SEQ ID NO: 148; or

xxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 145 and the Ctls comprises the amino acid sequence of SEQ ID NO: 149; or

xxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 147 and the Ctls comprises the amino acid sequence of SEQ ID NO: 149; or

xxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 150 and the Ctls comprises the amino acid sequence of SEQ ID NO: 149; or

xxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 150 and the Ctls comprises the amino acid sequence of SEQ ID NO: 151; or

xxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 152 and the Ctls comprises the amino acid sequence of SEQ ID NO: 146; or

xxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 154 and the Ctls comprises the amino acid sequence of SEQ ID NO: 155; or

xxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 145 and the Ctls comprises the amino acid sequence of SEQ ID NO: 155; or

xxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 145 and the Ctls comprises the amino acid sequence of SEQ ID NO: 156; or

xxx) the Ntls comprises the amino acid sequence of SEQ ID NO: 154 and the Ctls comprises the amino acid sequence of SEQ ID NO: 146; or

xxxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 157 and the Ctls comprises the amino acid sequence of SEQ ID NO: 146; or

xxxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 158 and the Ctls comprises the amino acid sequence of SEQ ID NO: 146; or

xxxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 160 and the Ctls comprises the amino acid sequence of SEQ ID NO: 161; or

xxxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 162 and the Ctls comprises the amino acid sequence of SEQ ID NO: 163; or

xxxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 164 and the Ctls comprises the amino acid sequence of SEQ ID NO: 165; or

xxxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 166 and the Ctls comprises the amino acid sequence of SEQ ID NO: 167; or

xxxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 170 and the Ctls comprises the amino acid sequence of SEQ ID NO: 134; or

xxxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 173 and the Ctls comprises the amino acid sequence of SEQ ID NO: 174; or

xxxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 175 and the Ctls comprises the amino acid sequence of SEQ ID NO: 176; or

xl) the Ntls comprises the amino acid sequence of SEQ ID NO: 177 and the Ctls comprises the amino acid sequence of SEQ ID NO: 178; or

xli) the Ntls comprises the amino acid sequence of SEQ ID NO: 179 and the Ctls comprises the amino acid sequence of SEQ ID NO: 180; or

xlii) the Ntls comprises the amino acid sequence of SEQ ID NO: 181 and the Ctls comprises the amino acid sequence of SEQ ID NO: 182; or

xliii) the Ntls comprises the amino acid sequence of SEQ ID NO: 183 and the Ctls comprises the amino acid sequence of SEQ ID NO: 184; or

xliv) the Ntls comprises the amino acid sequence of SEQ ID NO: 185 and the Ctls comprises the amino acid sequence of SEQ ID NO: 186; or

xlv) the Ntls comprises the amino acid sequence of SEQ ID NO: 187 and the Ctls comprises the amino acid sequence of SEQ ID NO: 188; or

xlvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 189 and the Ctls comprises the amino acid sequence of SEQ ID NO: 190; or

xlvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 189 and the Ctls comprises the amino acid sequence of SEQ ID NO: 191; or

xlviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 189 and the Ctls comprises the amino acid sequence of SEQ ID NO: 184; or

xlix) the Ntls comprises the amino acid sequence of SEQ ID NO: 189 and the Ctls comprises the amino acid sequence of SEQ ID NO: 192; or

l) the Ntls comprises the amino acid sequence of SEQ ID NO: 193 and the Ctls comprises the amino acid sequence of SEQ ID NO: 134; or

li) the Ntls comprises the amino acid sequence of SEQ ID NO: 194 and the Ctls comprises the amino acid sequence of SEQ ID NO: 195; or

Iii) the Ntls comprises the amino acid sequence of SEQ ID NO: 196 and the Ctls comprises the amino acid sequence of SEQ ID NO: 197; or

liii) the Ntls comprises the amino acid sequence of SEQ ID NO: 198 and the Ctls comprises the amino acid sequence of SEQ ID NO: 199; or

liv) the Ntls comprises the amino acid sequence of SEQ ID NO: 198 and the Ctls comprises the amino acid sequence of SEQ ID NO: 200; or

lv) the Ntls comprises the amino acid sequence of SEQ ID NO: 201 and the Ctls comprises the amino acid sequence of SEQ ID NO: 202; or

lvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 203 and the Ctls comprises the amino acid sequence of SEQ ID NO: 169; or

lvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 204 and the Ctls comprises the amino acid sequence of SEQ ID NO: 205; or

lviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 206 and the Ctls comprises the amino acid sequence of SEQ ID NO: 200; or

lix) the Ntls comprises the amino acid sequence of SEQ ID NO: 206 and the Ctls comprises the amino acid sequence of SEQ ID NO: 208; or

lx) the Ntls comprises the amino acid sequence of SEQ ID NO: 209 and the Ctls comprises the amino acid sequence of SEQ ID NO: 210; or

lxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 211 and the Ctls comprises the amino acid sequence of SEQ ID NO: 212; or

lxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 213 and the Ctls comprises the amino acid sequence of SEQ ID NO: 214; or

lxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 215 and the Ctls comprises the amino acid sequence of SEQ ID NO: 216; or

lxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 217 and the Ctls comprises the amino acid sequence of SEQ ID NO: 218; or

lxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 219 and the Ctls comprises the amino acid sequence of SEQ ID NO: 220; or

lxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 198 and the Ctls comprises the amino acid sequence of SEQ ID NO: 221; or

lxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 224 and the Ctls comprises the amino acid sequence of SEQ ID NO: 225; or

lxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 228 and the Ctls comprises the amino acid sequence of SEQ ID NO: 230; or

lxx) the Ntls comprises the amino acid sequence of SEQ ID NO: 231 and the Ctls comprises the amino acid sequence of SEQ ID NO: 221; or

lxxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 232 and the Ctls comprises the amino acid sequence of SEQ ID NO: 233; or

lxxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 234 and the Ctls comprises the amino acid sequence of SEQ ID NO: 235; or

lxxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 236 and the Ctls comprises the amino acid sequence of SEQ ID NO: 237; or

lxxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 238 and the Ctls comprises the amino acid sequence of SEQ ID NO: 140; or

lxxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 241 and the Ctls comprises the amino acid sequence of SEQ ID NO: 240; or

lxxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 242 and the Ctls comprises the amino acid sequence of SEQ ID NO: 243; or

lxxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 249 and the Ctls comprises the amino acid sequence of SEQ ID NO: 250; or

lxxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 251 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or

lxxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 257 and the Ctls comprises the amino acid sequence of SEQ ID NO: 258; or

lxxx) the Ntls comprises the amino acid sequence of SEQ ID NO: 259 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or

lxxxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 260 and the Ctls comprises the amino acid sequence of SEQ ID NO: 261; or

lxxxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 262 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or

lxxxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 263 and the Ctls comprises the amino acid sequence of SEQ ID NO: 264; or

lxxxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 265 and the Ctls comprises the amino acid sequence of SEQ ID NO: 266; or

lxxxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 267 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or

lxxxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 268 and the Ctls comprises the amino acid sequence of SEQ ID NO: 264; or

lxxxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 269 and the Ctls comprises the amino acid sequence of SEQ ID NO: 270; or

lxxxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 268 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or

lxxxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 273 and the Ctls comprises the amino acid sequence of SEQ ID NO: 274; or

xc) the Ntls comprises the amino acid sequence of SEQ ID NO: 275 and the Ctls comprises the amino acid sequence of SEQ ID NO: 276; or

xci) the Ntls comprises the amino acid sequence of SEQ ID NO: 277 and the Ctls comprises the amino acid sequence of SEQ ID NO: 278; or

xcii) the Ntls comprises the amino acid sequence of SEQ ID NO: 279 and the Ctls comprises the amino acid sequence of SEQ ID NO: 280; or

xciii) the Ntls comprises the amino acid sequence of SEQ ID NO: 281 and the Ctls comprises the amino acid sequence of SEQ ID NO: 282; or

xciv) the Ntls comprises the amino acid sequence of SEQ ID NO: 281 and the Ctls comprises the amino acid sequence of SEQ ID NO: 283; or

xcv) the Ntls comprises the amino acid sequence of SEQ ID NO: 284 and the Ctls comprises the amino acid sequence of SEQ ID NO: 285; or

xcvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 286 and the Ctls comprises the amino acid sequence of SEQ ID NO: 287; or

xcvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 288 and the Ctls comprises the amino acid sequence of SEQ ID NO: 289; or

xcviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 290 and the Ctls comprises the amino acid sequence of SEQ ID NO: 278; or

xcix) the Ntls comprises the amino acid sequence of SEQ ID NO: 291 and the Ctls comprises the amino acid sequence of SEQ ID NO: 292; or

c) the Ntls comprises the amino acid sequence of SEQ ID NO: 268 and the Ctls comprises the amino acid sequence of SEQ ID NO: 293; or

ci) the Ntls comprises the amino acid sequence of SEQ ID NO: 294 and the Ctls comprises the amino acid sequence of SEQ ID NO: 295; or

cii) the Ntls comprises the amino acid sequence of SEQ ID NO: 298 and the Ctls comprises the amino acid sequence of SEQ ID NO: 299; or

ciii) the Ntls comprises the amino acid sequence of SEQ ID NO: 300 and the Ctls comprises the amino acid sequence of SEQ ID NO: 301; or

civ) the Ntls comprises the amino acid sequence of SEQ ID NO: 302 and the Ctls comprises the amino acid sequence of SEQ ID NO: 299; or

cv) the Ntls comprises the amino acid sequence of SEQ ID NO: 304 and the Ctls comprises the amino acid sequence of SEQ ID NO: 305; or

cvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 306 and the Ctls comprises the amino acid sequence of SEQ ID NO: 307; or

cvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 320 and the Ctls comprises the amino acid sequence of SEQ ID NO: 321; or

cviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 323 and the Ctls comprises the amino acid sequence of SEQ ID NO: 324; or

cix) the Ntls comprises the amino acid sequence of SEQ ID NO: 330 and the Ctls comprises the amino acid sequence of SEQ ID NO: 331; or

cx) the Ntls comprises the amino acid sequence of SEQ ID NO: 334 and the Ctls comprises the amino acid sequence of SEQ ID NO: 335; or

cxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 336 and the Ctls comprises the amino acid sequence of SEQ ID NO: 337; or

cxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 338 and the Ctls comprises the amino acid sequence of SEQ ID NO: 339; or

cxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 340 and the Ctls comprises the amino acid sequence of SEQ ID NO: 341; or

cxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 342 and the Ctls comprises the amino acid sequence of SEQ ID NO: 343; or

cxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 344 and the Ctls comprises the amino acid sequence of SEQ ID NO: 339; or

cxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 345 and the Ctls comprises the amino acid sequence of SEQ ID NO: 346; or

cxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 347 and the Ctls comprises the amino acid sequence of SEQ ID NO: 348; or

cxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 349 and the Ctls comprises the amino acid sequence of SEQ ID NO: 350; or

cxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 353 and the Ctls comprises the amino acid sequence of SEQ ID NO: 354; or

cxx) the Ntls comprises the amino acid sequence of SEQ ID NO: 355 and the Ctls comprises the amino acid sequence of SEQ ID NO: 339; or

cxxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 356 and the Ctls comprises the amino acid sequence of SEQ ID NO: 357; or

cxxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 358 and the Ctls comprises the amino acid sequence of SEQ ID NO: 359; or

cxxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 360 and the Ctls comprises the amino acid sequence of SEQ ID NO: 361; or

cxxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 364 and the Ctls comprises the amino acid sequence of SEQ ID NO: 365; or

cxxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 373 and the Ctls comprises the amino acid sequence of SEQ ID NO: 374; or

cxxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 375 and the Ctls comprises the amino acid sequence of SEQ ID NO: 374; or

cxxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 378 and the Ctls comprises the amino acid sequence of SEQ ID NO: 379; or

cxxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 382 and the Ctls comprises the amino acid sequence of SEQ ID NO: 383; or

cxxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 384 and the Ctls comprises the amino acid sequence of SEQ ID NO: 385; or

cxxx) the Ntls comprises the amino acid sequence of SEQ ID NO: 386 and the Ctls comprises the amino acid sequence of SEQ ID NO: 387; or

cxxxi) the Ntls comprises the amino acid sequence of SEQ ID NO: 388 and the Ctls comprises the amino acid sequence of SEQ ID NO: 389; or

cxxxii) the Ntls comprises the amino acid sequence of SEQ ID NO: 390 and the Ctls comprises the amino acid sequence of SEQ ID NO: 385; or

cxxxiii) the Ntls comprises the amino acid sequence of SEQ ID NO: 391 and the Ctls comprises the amino acid sequence of SEQ ID NO: 385; or

cxxxiv) the Ntls comprises the amino acid sequence of SEQ ID NO: 392 and the Ctls comprises the amino acid sequence of SEQ ID NO: 393; or

cxxxv) the Ntls comprises the amino acid sequence of SEQ ID NO: 394 and the Ctls comprises the amino acid sequence of SEQ ID NO: 395; or

cxxxvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 396 and the Ctls comprises the amino acid sequence of SEQ ID NO: 397; or

cxxxvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 398 and the Ctls comprises the amino acid sequence of SEQ ID NO: 399; or

cxxxviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 400 and the Ctls comprises the amino acid sequence of SEQ ID NO: 401; or

cxxxix) the Ntls comprises the amino acid sequence of SEQ ID NO: 402 and the Ctls comprises the amino acid sequence of SEQ ID NO: 403; or

cxl) the Ntls comprises the amino acid sequence of SEQ ID NO: 404 and the Ctls comprises the amino acid sequence of SEQ ID NO: 405; or

cxli) the Ntls comprises the amino acid sequence of SEQ ID NO: 406 and the Ctls comprises the amino acid sequence of SEQ ID NO: 397; or

cxlii) the Ntls comprises the amino acid sequence of SEQ ID NO: 407 and the Ctls comprises the amino acid sequence of SEQ ID NO: 408; or

cxliii) the Ntls comprises the amino acid sequence of SEQ ID NO: 409 and the Ctls comprises the amino acid sequence of SEQ ID NO: 393; or

cxliv) the Ntls comprises the amino acid sequence of SEQ ID NO: 406 and the Ctls comprises the amino acid sequence of SEQ ID NO: 411; or

cxlv) the Ntls comprises the amino acid sequence of SEQ ID NO: 412 and the Ctls comprises the amino acid sequence of SEQ ID NO: 413; or

cxlvi) the Ntls comprises the amino acid sequence of SEQ ID NO: 414 and the Ctls comprises the amino acid sequence of SEQ ID NO: 405; or

cxlvii) the Ntls comprises the amino acid sequence of SEQ ID NO: 415 and the Ctls comprises the amino acid sequence of SEQ ID NO: 416; or

cxlviii) the Ntls comprises the amino acid sequence of SEQ ID NO: 417 and the Ctls comprises the amino acid sequence of SEQ ID NO: 405; or

cxlix) the Ntls comprises the amino acid sequence of SEQ ID NO: 418 and the Ctls comprises the amino acid sequence of SEQ ID NO: 419; or

cl) the Ntls comprises the amino acid sequence of SEQ ID NO: 420 and the Ctls comprises the amino acid sequence of SEQ ID NO: 421; or

cli) the Ntls comprises the amino acid sequence of SEQ ID NO: 422 and the Ctls comprises the amino acid sequence of SEQ ID NO: 423; or

clii) the Ntls comprises the amino acid sequence of SEQ ID NO: 424 and the Ctls comprises the amino acid sequence of SEQ ID NO: 425; or

cliii) the Ntls comprises the amino acid sequence of SEQ ID NO: 426 and the Ctls comprises the amino acid sequence of SEQ ID NO: 427; or

cliv) the Ntls comprises the amino acid sequence of SEQ ID NO: 429 and the Ctls comprises the amino acid sequence of SEQ ID NO: 428; or

clv) the Ntls comprises the amino acid sequence of SEQ ID NO: 27 and the Ctls comprises the amino acid sequence of SEQ ID NO: 40.

5. The antibody or fragment thereof according to claim 1 , wherein the amino acid stretch present between

i) amino acid residue HC res25 according to Kabat and amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1;

ii) amino acid residue HC res51 according to Kabat and amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2;

iii) amino acid residue HC res92 according to Kabat and amino acid residue HC res106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3;

iv) amino acid residue LC res26 according to Kabat and amino acid residue LC res 32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1;

v) amino acid residue LC res49 according to Kabat and amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or

vi) amino acid residue LC res88 according to Kabat and amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL3

comprises the sequence of any one of SEQ ID NOs 52 to 64 or a sequence having at least 95% sequence identity with any one of SEQ ID NOs 52 to 64.

6. The antibody or fragment thereof according to claim 1 , comprising at least one further natriuretic peptide, wherein said ANP and said at least one further natriuretic peptide are incorporated within at least two separate CDR regions, and wherein said at least one further natriuretic peptide is selected from BNP and CNP.

7. The antibody or fragment thereof according to claim 1 , wherein said antibody or fragment thereof comprises the amino acid sequence of SEQ ID NO: 65.

8. The antibody or fragment thereof according to claim 1 ,

wherein:

(i) the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 67 to 79; or

(ii) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 65 and the light chain comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 80 and 81.

9. The antibody fragment according to claim 1 , wherein said antibody fragment is selected from the group consisting of Fab, Fab′, Fab′-SH, F(ab′)2, and Fv fragments; diabodies; single domain antibodies (Dabs); linear antibodies; single-chain antibody molecules (scFv); and disulfide-stabilized Fv antibody fragments (dsFv).

10. A composition comprising the antibody or fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.

11. A nucleic acid or a mixture of nucleic acids encoding the antibody or fragment thereof according to claim 1 .

12. A host cell comprising the nucleic acid or the mixture of nucleic acids according to claim 11 .

13. A process for producing an antibody or fragment thereof, comprising culturing the host cell according to claim 12 under conditions suitable for expression of the antibody or fragment thereof.

14. The antibody or fragment thereof according to claim 8 , wherein the light chain comprises of the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises of the amino acid sequence of any one of SEQ ID NOs: 67 to 79.

15. The antibody or fragment thereof according to claim 14 , wherein the light chain comprises of the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises of the amino acid sequence of SEQ ID NO: 76.

16. The antibody or fragment thereof according to claim 8 , wherein the light chain is SEQ ID NO: 66 and the heavy chain is SEQ ID NOs: 67 to 79.

17. The antibody or fragment thereof according to claim 14 , wherein the light chain is SEQ ID NO: 66 and the heavy chain is SEQ ID NO: 76.

18. The antibody or fragment thereof according to claim 1 , wherein at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2020
From: MAYER-BARTSCHMID, ANKE; BROCKSCHNIEDER, DAMIAN; GEERTZ, MARCEL; GREVEN, SIMONE; HOFMEISTER, LUCAS HUDSON; JÖRISSEN, HANNAH; MAHLERT, CHRISTOPH; MARQUARDT, TOBIAS; MATHAR, IKA; MONDRITZKI, THOMAS; NOACK, CLAUDIA; TEBBE, JAN; WALSH, STUART; WEBER, ERNST; WILMEN, ANDREAS; WUNDER, FRANK
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 054697/0135 →
Priority Claims (1)
EP 18167102 · Apr 12, 2018 · regional
Continuity (1)
Related Publication 20210139555A1 · May 13, 2021
References Cited (104)
US 4399216A · Axel · 1983 [cited by applicant]
US 4510245A · Cousens · 1985 [cited by applicant]
US 4634665A · Axel · 1987 [cited by applicant]
US 4816397A · Boss · 1989 [cited by applicant]
US 4968615A · Koszinowski · 1990 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5179017A · Axel · 1993 [cited by applicant]
US 5288931A · Chang · 1994 [cited by examiner]
US 7112660B1 · Domingues · 2006 [cited by examiner]
US 7521424B2 · Rosen · 2009 [cited by applicant]
US 7705043B2 · Alonso-alija et al. · 2010 [cited by applicant]
US 7781470B2 · Alonso-alija et al. · 2010 [cited by applicant]
US 8796324B2 · Bruggemeier et al. · 2014 [cited by applicant]
US 9193777B2 · Burnett, Jr. · 2015 [cited by applicant]
US 9687476B2 · Fürstner et al. · 2017 [cited by applicant]
US 9993476B2 · Follmann et al. · 2018 [cited by applicant]
US 20030045474A1 · Sailer · 2003 [cited by examiner]
US 20040253242A1 · Bowdish · 2004 [cited by examiner]
US 20070292411A1 · Salcedo · 2007 [cited by applicant]
US 20100310561A1 · Canada · 2010 [cited by applicant]
US 20120114659A1 · Waterman · 2012 [cited by applicant]
US 20140148390A1 · Haupts · 2014 [cited by applicant]
US 20140154743A1 · Levy · 2014 [cited by examiner]
US 20210079056A1 · Brockschnieder · 2021 [cited by applicant]
US 20210147504A1 · Brockschnieder · 2021 [cited by applicant]
CN 103087191A · 2013 [cited by applicant]
CN 103649116A · 2014 [cited by applicant]
EP 2432489B1 · 2016 [cited by applicant]
WO 0006568A1 · 2000 [cited by applicant]
WO 0006569A1 · 2000 [cited by applicant]
WO 0119355A2 · 2001 [cited by applicant]
WO 0119776A2 · 2001 [cited by applicant]
WO 0119778A1 · 2001 [cited by applicant]
WO 0119780A2 · 2001 [cited by applicant]
WO 0119780A3 · 2001 [cited by applicant]
WO 0119776A3 · 2001 [cited by applicant]
WO 0242301A1 · 2002 [cited by applicant]
WO 02070462A1 · 2002 [cited by applicant]
WO 02070510A2 · 2002 [cited by applicant]
WO 02078612A2 · 2002 [cited by applicant]
WO 02070510A3 · 2003 [cited by applicant]
WO 03095451A1 · 2003 [cited by applicant]
WO 2005060642A2 · 2005 [cited by applicant]
WO 2005082004A2 · 2005 [cited by applicant]
WO 2005060642A3 · 2005 [cited by applicant]
WO 2006107124A1 · 2006 [cited by applicant]
WO 2008079995A2 · 2008 [cited by applicant]
WO 2008079995A3 · 2008 [cited by applicant]
WO 2005082004A3 · 2008 [cited by applicant]
WO 2008136611A1 · 2008 [cited by applicant]
WO 2008154226A1 · 2008 [cited by applicant]
WO 2009033094A2 · 2009 [cited by applicant]
WO 2010054007A1 · 2010 [cited by applicant]
WO 2010105770A1 · 2010 [cited by applicant]
WO 2010117760A2 · 2010 [cited by applicant]
WO 2010117760A3 · 2010 [cited by applicant]
WO 2010135541A2 · 2010 [cited by applicant]
WO 2011104322A1 · 2011 [cited by applicant]
WO 2011147809A1 · 2011 [cited by applicant]
WO 2012004258A1 · 2012 [cited by applicant]
WO 2012028647A1 · 2012 [cited by applicant]
WO 2012059549A1 · 2012 [cited by applicant]
WO 2015006337A2 · 2015 [cited by applicant]
WO 2016071212A1 · 2016 [cited by applicant]
Tokuriki et al., (2009, Curr. Opin. Struc. Biol. 19:596-604). [cited by examiner]
Fenton et al. (2020, Medicinal Chemistry Research 29:1133-1146). [cited by examiner]
Bhattacharya et al. (2017, PLoS One 12(3): e0171355, https://doi.org/10.1371/journal.pone.0171355). [cited by examiner]
Alaoui-Ismaili (2009, Cytokine Growth Factor Rev. 20(5-6):501-7). [cited by examiner]
Guo et al. (2004, PNAS USA 101(25):9205-10). [cited by examiner]
Ulloa-Aguirre et al. (2004, Traffic 5:821-837). [cited by examiner]
Bernier et al. (2004, Curr. Opin. Pharmacol. 4:528-533). [cited by examiner]
Fillippovic O. B. et al., Biochemical basis for human life activity. Textbook for for college-level.—M.: Vlados, 2005.—407 p. il.; see p. 49-50 and 70. (Partial English Translation only.). [cited by applicant]
Roitt A. et al. (2000), Immunology. Translation from English—M.: Mir, 2000.—592 p. ill.; p. 150. (Partial English Translation only.). [cited by applicant]
Šarošina I. A. et al. (2003). “The role of natriuretic peptides for the diagnosis of heart failure,” Russian Journal of Cardiology, N 2(40): 81-86. [cited by applicant]
Anand-Srivastava, M.B. (Jun. 2005). “ Natriuretic peptide receptor-C signaling and regulation,” Peptides 26(6): 1044-1059. [cited by applicant]
Anker, S.D. et al. (Mar. 21, 2015). “Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies,” Eur Heart J. 36 (12): 715-723. [cited by applicant]
Baliga, R.S. et al. (Jul. 2014). “Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis,” British Journal of Pharmacology 171(14): 3463-3475. [cited by applicant]
Buglioni, A. et al. (2016). “New Pharmacological Strategies to Increase cGMP,” Annu Rev .Med. 67: 229-243. [cited by applicant]
Dahrouj, M et al. (Jan. 2013). “C-Type Natriuretic Peptide Protects the Retinal Pigment Epithelium against Advanced Glycation End Product-Induced Barrier Dysfunction.” J Pharmacol Exp Ther. 344 (1): 96-102. [cited by applicant]
Edelson, J.D. et al. (Apr. 2013). “In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-D-Ala-Gly-Arg-D-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Argmimetic]-NH2) natriuretic pepti… [cited by applicant]
Hunt, P.J. et al. (1994). “Bioactivity and Metabolism of C-Type Natriuretic Peptide in Normal Man*” Journal of Clinical Endocrinology and Metabolism, 78(6):1428-1435. [cited by applicant]
International Search Report mailed May 29, 2019 for PCT International Application No. PCT/EP2019/059093, filed Apr. 10, 2019, 4 pages. [cited by applicant]
Kimura, K. et al. (2007). “ANP is cleared much faster than BNP in patients with congestive heart failure,” Eur J Clin Pharmacol, 63:699-702. [cited by applicant]
Kimura, T. et al. (2016). “C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice,” Respiratory Research, 17(19):1-17. [cited by applicant]
Knowles, J.W. et al. (2001). “Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice,” J.Clin. Invest. 107(8): 975-984. [cited by applicant]
Lee, C. et al. (2007). “Pharmacokinetic and pharmacodynamic study of a novel chimeric natriuretic peptide, CD-NP, in the normal dog,” BMC Pharmacology 7 (Suppl I): P38. [cited by applicant]
Lumsden, N.G. et al. (2010). “C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target,” Current Pharmaceutical Design, 16:4080-4088. [cited by applicant]
McKie, P. et al. (2010) “CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease,” Curr Heart Fail Rep, 7:93-99. [cited by applicant]
McKie, P.M. et al. (Dec. 2010). “A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension,” Hypertension 56 (6): 1152-1159. [cited by applicant]
Mitaka, C. et al. (2014) “Effects of atrial natriuretic peptide on inter-organ crosstalk among the kidney, lung, and heart in a rat model of renal ischemia-reperfusion injury,” Intensive Care Medicine Experimental, 2(28… [cited by applicant]
Moyes, A.J. et al. (2014), “Endothelial C-type natriuretic peptide maintains vascular homeostasis,” The Journal of Clinical Investigation, 124(9):4039-4051. [cited by applicant]
Pan, S. et al. (Jul. 7, 2009). “Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide,” PNAS 106 (27): 11282-11287. [cited by applicant]
Potter, L. et al. (2009) “Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications,” Handb Exp Pharmacol., 191:341-66. [cited by applicant]
Wendt, D. J. et al. (Apr. 2015). “Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3-Related Dwarfism,” J. Pharm… [cited by applicant]
Werner, F. et al. (2016) “Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice,” Basic Res Cardiol 111(22):1-16. [cited by applicant]
Woods, R. (2004) “Cardioprotective Functions of Atrial Natriuretic Peptide and B-Type Natriuretic Peptide: A Brief Review,” Clinical and Experimental Pharmacology and Physiology, 31:791-794. [cited by applicant]
Yasoda, A. et al. (2009). “Effects of natriuretic peptides on endochondral bone growth,” Clinical Calcium, 17(7):103-108. English Abstract. [cited by applicant]
International Search Report and Written Opinion, mailed May 17, 2019, for PCT Application No. PCT/EP2019/059101, filed Apr. 10, 2019, 10 pages. [cited by applicant]
International Search Report and Written Opinion, mailed May 20, 2019, for PCT Application No. PCT/EP2019/059103, filed Apr. 10, 2019, 11 pages. [cited by applicant]
Mezo, A.R., et al. (2012). “Atrial Natriuretic Peptide-Fc, ANP-Fc, Fusion Proteins: Semisynthesis, In Vitro Activity and Pharmacokinetics in Rats,” American Chemical Society, 23: 518-526. [cited by applicant]
Peng, J., et al. (Apr. 25, 2018). “Preparation of anti hCG single domain antibodies using antigen binding peptide engrafted antibody technology,” Chinese Journal of Biotechnology, 34(4): 569-577. English translation of … [cited by applicant]
Teng, S. et al. (2010, e-pub. Feb. 4, 2011). “Structural Assessment of the Effects of Amino Acid Substitutions on Protein Stability and Protein-Protein Interaction,” Int J Comput Biol Drug Des. 3(4):334-349. [cited by applicant]
Tobi, D. et al. (Dec. 14, 2005). “Structural Changes Involved in Protein Binding Correlate with Intrinsic motions of Proteins in the Unbound State,” PNAS 102(52):18908-18913. [cited by applicant]
Wang, W. et al. (Nov. 2004). “AlbuBNP, a Recombinant B-Type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure,” Pharmaceutical Research 21(11): 2105-2110. [cited by applicant]